Cargando…
A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
BACKGROUND: In preclinical models, recombinant human relaxin-2 (serelaxin) had anti-fibrotic effects and ameliorated portal hypertension (PH). A small exploratory study in patients with cirrhosis also suggested that serelaxin could reduce portal pressure. METHODS: In a phase 2, double-blind, randomi...
Autores principales: | Gifford, Fiona J., Dunne, Philip D. J., Weir, Graeme, Ireland, Hamish, Graham, Catriona, Tuck, Sharon, Hayes, Peter C., Fallowfield, Jonathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066808/ https://www.ncbi.nlm.nih.gov/pubmed/32164767 http://dx.doi.org/10.1186/s13063-020-4203-9 |
Ejemplares similares
-
Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
por: Snowdon, Victoria K., et al.
Publicado: (2017) -
Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015) -
The Eye as a Non-Invasive Window to the Microcirculation in Liver Cirrhosis: A Prospective Pilot Study
por: Gifford, Fiona J, et al.
Publicado: (2020) -
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
por: Garcia‐Tsao, Guadalupe, et al.
Publicado: (2018) -
Kein proviosorischer Stopp am CERN
Publicado: (2008)